These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [A Familial Non Medullary Thyroid Carcinoma (FNMTC) : a clinical and genetic update]. Valdes-Socin H; Palmeira L; Burlacu MC; Daly AF; Bours V; Beckers A Rev Med Liege; 2016 Dec; 71(12):557-561. PubMed ID: 28387096 [TBL] [Abstract][Full Text] [Related]
3. Familial nonmedullary thyroid cancer: a review of the genetics. Khan A; Smellie J; Nutting C; Harrington K; Newbold K Thyroid; 2010 Jul; 20(7):795-801. PubMed ID: 20465534 [TBL] [Abstract][Full Text] [Related]
4. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer. Hińcza K; Kowalik A; Kowalska A Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31247975 [TBL] [Abstract][Full Text] [Related]
5. Familial non-medullary thyroid carcinoma (FNMTC): analysis of fPTC/PRN, NMTC1, MNG1 and TCO susceptibility loci and identification of somatic BRAF and RAS mutations. Cavaco BM; Batista PF; Martins C; Banito A; do Rosário F; Limbert E; Sobrinho LG; Leite V Endocr Relat Cancer; 2008 Mar; 15(1):207-15. PubMed ID: 18310288 [TBL] [Abstract][Full Text] [Related]
6. Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. Vriens MR; Suh I; Moses W; Kebebew E Thyroid; 2009 Dec; 19(12):1343-9. PubMed ID: 20001717 [TBL] [Abstract][Full Text] [Related]
7. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC). Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600 [TBL] [Abstract][Full Text] [Related]
8. HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer. Weeks AL; Wilson SG; Ward L; Goldblatt J; Hui J; Walsh JP BMC Med Genet; 2016 Aug; 17(1):60. PubMed ID: 27530615 [TBL] [Abstract][Full Text] [Related]
9. A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci. Tsilchorozidou T; Vafiadou E; Yovos JG; Romeo G; McKay J; Lesueur F; Bonora E Thyroid; 2005 Dec; 15(12):1349-54. PubMed ID: 16405407 [TBL] [Abstract][Full Text] [Related]
10. Mapping a new familial thyroid epithelial neoplasia susceptibility locus to chromosome 8p23.1-p22 by high-density single-nucleotide polymorphism genome-wide linkage analysis. Cavaco BM; Batista PF; Sobrinho LG; Leite V J Clin Endocrinol Metab; 2008 Nov; 93(11):4426-30. PubMed ID: 18765515 [TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Management of Hereditary Thyroid Cancer. Bano G; Hodgson S Recent Results Cancer Res; 2016; 205():29-44. PubMed ID: 27075347 [TBL] [Abstract][Full Text] [Related]
12. Familial non-medullary thyroid carcinoma: clinico-pathological features, current knowledge and novelty regarding genetic risk factors. Cirello V Minerva Endocrinol (Torino); 2021 Mar; 46(1):5-20. PubMed ID: 33045820 [TBL] [Abstract][Full Text] [Related]
13. HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer. Zhang T; Xing M J Natl Cancer Inst; 2016 Jun; 108(6):djv415. PubMed ID: 26832773 [TBL] [Abstract][Full Text] [Related]
14. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer. Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673 [TBL] [Abstract][Full Text] [Related]
15. Genetic predisposition to papillary thyroid cancer. Kula D; Kalemba M; Jurecka-Lubieniecka B; Puch Z; Kowalska M; Tyszkiewicz T; Kowal M; Handkiewicz-Junak D Endokrynol Pol; 2010; 61(5):486-9. PubMed ID: 21049463 [TBL] [Abstract][Full Text] [Related]
16. Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer. Miasaki FY; Fuziwara CS; Carvalho GA; Kimura ET Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33218058 [TBL] [Abstract][Full Text] [Related]
17. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers. Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516 [TBL] [Abstract][Full Text] [Related]
18. Segregation and expression analyses of hyaluronan-binding protein 2 (HABP2): insights from a large series of familial non-medullary thyroid cancers and literature review. Colombo C; Muzza M; Proverbio MC; Ercoli G; Perrino M; Cirello V; Vicentini L; Ferrero S; Fugazzola L Clin Endocrinol (Oxf); 2017 Jun; 86(6):837-844. PubMed ID: 28222214 [TBL] [Abstract][Full Text] [Related]
19. An update on familial nonmedullary thyroid cancer. Ammar SA; Alobuia WM; Kebebew E Endocrine; 2020 Jun; 68(3):502-507. PubMed ID: 32162184 [TBL] [Abstract][Full Text] [Related]
20. Letter regarding the article: "Multiple HABP2 variants in familial papillary thyroid carcinoma: Contribution of a group of "thyroid-checked" controls" by Kern et al. Colombo C; Fugazzola L; Muzza M; Proverbio MC; Cirello V Eur J Med Genet; 2018 Feb; 61(2):104-105. PubMed ID: 28779995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]